# Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

> **NCT00998010** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** bortezomib + temozolomide+ radiation therapy

## Key facts

- **NCT ID:** NCT00998010
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-03
- **Primary completion:** 2016-03-29
- **Final completion:** 2018-04-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00998010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00998010, "Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00998010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*